查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604585

抗凝血酶市场：按配方、来源、类型、途径和应用划分 - 2025-2030 年全球预测

Antithrombin Market by Formulation (Liquid, Lyophilized), Source (Goat Milk, Human), Type, Route, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗凝血酶市值为7.9609亿美元，预计2024年将达到8.7687亿美元，复合年增长率为10.24%，到2030年将达到15.7532亿美元。

抗凝血酶是一种重要的血浆蛋白，透过抑制凝血酶和参与血液凝固过程的其他酵素来帮助调节血液凝固。抗凝血酶的需求源于其在降低与深层静脉栓塞症、肺动脉栓塞和其他凝血障碍相关的风险以及预防异常血栓形成方面的重要作用。它主要用于治疗药物，特别是在涉及心肺体外迴圈和肝素治疗的手术中，以帮助调节抗凝血作用。最终用途主要包括医疗机构、血液学研究人员和专注于抗凝血治疗的製药公司。抗凝血酶市场受到多种成长要素的影响，例如凝血障碍盛行率的增加以及促进重组蛋白药物开发的生物技术的进步。扩大用于治疗遗传性抗凝血酶缺陷以及开发具有更高功效和递送效果的新製剂的潜力正在增加。新兴市场提供了医疗保健支出增加和血液疾病创新诊断技术开发等机会。然而，该市场面临诸如高製造成本和严格的生技药品监管要求等限制，这可能会延迟产品核可。生产重组蛋白的复杂性也构成了重大挑战。该行业可以从合成生物学研究中受益，以降低生产成本、提高产量并创造更稳定的配方。提高抗凝血酶生物有效性和稳定性的药物传输系统创新也可能推动市场成长。抗凝血酶市场是一个竞争激烈的市场，主要企业都专注于策略伙伴关係和研究合作，以扩大产品系列。总体而言，未来的市场开拓将取决于利用技术进步来开发具有成本效益和治疗有效的抗凝血酶产品，同时克服监管和经济挑战。

主要市场统计
基准年[2023] 79609万美元
预计年份 [2024] 87687万美元
预测年份 [2030] 15.7532 亿美元
复合年增长率（%） 10.24%

市场动态：揭示快速发展的抗凝血酶市场的关键市场洞察

抗凝血酶市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 抗凝血酶缺乏增加，手术期间出血增加
    • 快速诊断测试的利用和抗凝血酶的需求
    • 提高消费者对血栓性疾病的认识
  • 市场限制因素
    • 抗凝血酶的资本集中生产
  • 市场机会
    • 抗凝血酵素药物中越来越多地采用天然药物
    • 开发具有成本效益的抗凝血酶生产程序的技术进步
  • 市场挑战
    • 抗凝血酶缺乏症实验室检测的局限性

波特的五力：驾驭抗凝血酶市场的策略工具

波特的五力架构是了解抗凝血酶市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗凝血酶市场的外部影响

外部宏观环境因素在塑造抗凝血酶市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗凝血酶市场的竞争状况

抗凝血酶市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗凝血酶市场供应商的绩效评估

FPNV定位矩阵是评估抗凝血酶市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製抗凝血酶市场的成功之路

抗凝血酶市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 抗凝血酶缺乏增加和术中出血增加
      • 快速诊断测试的利用和抗凝血酶的需求
      • 消费者对血栓性疾病的认识提高
    • 抑制因素
      • 抗凝血酶的资本密集型生产
    • 机会
      • 抗凝血酵素中天然物质的采用增加
      • 开发具有成本效益的抗凝血酶生产程序的技术进步
    • 任务
      • 抗凝血酶缺乏症临床检测的局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 处方抗凝血酶市场

  • 液体
  • 冷冻干燥

第七章抗凝血酶市场：依来源分类

  • 羊奶
  • 人类

第八章抗凝血酶市场：依类型

  • 抗凝血物
  • 抗血小板药
  • 溶栓药物

第 9 章 抗凝血酶市场：按路线

  • 口服
  • 胃肠外的

第10章抗凝血酶市场：依应用分类

  • 诊断
  • 调查
  • 治疗药物

第十一章美洲抗凝血酶市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区抗凝血酶市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的抗凝血酶市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Bio-Techne Corporation
  • BioPharm Laboratories, LLC
  • CSL Limited
  • Diapharma Group, Inc.
  • European Medicines Agency
  • Genesis BioPharma
  • Grifols, SA
  • Kedrion SpA
  • Lee Biosolutions, Inc.
  • LFB USA, Inc.
  • Merck KGaA
  • Octapharma AG
  • Scripps Laboratories, Inc.
  • Siemens AG
  • SK Plasma
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • WebMD, LLC
Product Code: MRR-4358BACA8223

The Antithrombin Market was valued at USD 796.09 million in 2023, expected to reach USD 876.87 million in 2024, and is projected to grow at a CAGR of 10.24%, to USD 1,575.32 million by 2030.

Antithrombin is a vital plasma protein that helps regulate blood coagulation by inhibiting thrombin and other enzymes involved in the clotting process. The necessity of antithrombin arises from its critical role in preventing abnormal clot formation, thereby mitigating risks associated with conditions like deep vein thrombosis, pulmonary embolism, and other coagulation disorders. It finds application primarily in therapeutics, particularly in surgeries involving cardiopulmonary bypass and during heparin therapy, where it helps to regulate anticoagulation. The end-use scope primarily includes healthcare facilities, researchers in hematology, and pharmaceutical companies focusing on anticoagulant therapies. The antithrombin market is influenced by several growth factors, including the increasing prevalence of coagulation disorders and advancements in biotechnology that facilitate the development of recombinant protein drugs. There is a growing potential in expanding its use in treating genetic antithrombin deficiency and developing novel formulations with enhanced efficacy and delivery. Opportunities exist in emerging markets with rising healthcare expenditures and the deployment of innovative diagnostics for blood disorders. However, the market faces limitations such as high production costs and stringent regulatory requirements for biologics, which can delay product approvals. The complexity of manufacturing recombinant proteins also poses significant challenges. The industry could benefit from research into synthetic biology to lower production costs, enhance yield, and create more stable antithrombin formulations. Innovations in drug delivery systems that improve the bioavailability and stability of antithrombin could also drive market growth. The nature of the antithrombin market is competitive, with key players focusing on strategic partnerships and research collaborations to expand their product portfolios. Overall, future market development hinges on overcoming regulatory and economic challenges while harnessing technological advancements to develop cost-effective and therapeutically potent antithrombin products.

KEY MARKET STATISTICS
Base Year [2023] USD 796.09 million
Estimated Year [2024] USD 876.87 million
Forecast Year [2030] USD 1,575.32 million
CAGR (%) 10.24%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antithrombin Market

The Antithrombin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing occurrence of antithrombin deficiency and increased bleeding during surgeries
    • Utilization of rapid diagnostic tests and need for antithrombin
    • Increasing awareness of the thrombotic disease among consumers
  • Market Restraints
    • Capital-intensive production of antithrombin
  • Market Opportunities
    • Rising adoption of natural agents in antithrombins
    • Technological advancements in the development of cost-effective procedures in the production of antithrombin
  • Market Challenges
    • Limitations of lab testing of antithrombin deficiency

Porter's Five Forces: A Strategic Tool for Navigating the Antithrombin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antithrombin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antithrombin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antithrombin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antithrombin Market

A detailed market share analysis in the Antithrombin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antithrombin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antithrombin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antithrombin Market

A strategic analysis of the Antithrombin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antithrombin Market, highlighting leading vendors and their innovative profiles. These include Bio-Techne Corporation, BioPharm Laboratories, LLC, CSL Limited, Diapharma Group, Inc., European Medicines Agency, Genesis BioPharma, Grifols, S.A., Kedrion S.p.A., Lee Biosolutions, Inc., LFB USA, Inc., Merck KGaA, Octapharma AG, Scripps Laboratories, Inc., Siemens AG, SK Plasma, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and WebMD, LLC.

Market Segmentation & Coverage

This research report categorizes the Antithrombin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Formulation, market is studied across Liquid and Lyophilized.
  • Based on Source, market is studied across Goat Milk and Human.
  • Based on Type, market is studied across Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
  • Based on Route, market is studied across Oral and Parenteral.
  • Based on Application, market is studied across Diagnostics, Research, and Therapeutics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing occurrence of antithrombin deficiency and increased bleeding during surgeries
      • 5.1.1.2. Utilization of rapid diagnostic tests and need for antithrombin
      • 5.1.1.3. Increasing awareness of the thrombotic disease among consumers
    • 5.1.2. Restraints
      • 5.1.2.1. Capital-intensive production of antithrombin
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising adoption of natural agents in antithrombins
      • 5.1.3.2. Technological advancements in the development of cost-effective procedures in the production of antithrombin
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of lab testing of antithrombin deficiency
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antithrombin Market, by Formulation

  • 6.1. Introduction
  • 6.2. Liquid
  • 6.3. Lyophilized

7. Antithrombin Market, by Source

  • 7.1. Introduction
  • 7.2. Goat Milk
  • 7.3. Human

8. Antithrombin Market, by Type

  • 8.1. Introduction
  • 8.2. Anticoagulant
  • 8.3. Antiplatelet
  • 8.4. Thrombolytic Drugs

9. Antithrombin Market, by Route

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral

10. Antithrombin Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostics
  • 10.3. Research
  • 10.4. Therapeutics

11. Americas Antithrombin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antithrombin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antithrombin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bio-Techne Corporation
  • 2. BioPharm Laboratories, LLC
  • 3. CSL Limited
  • 4. Diapharma Group, Inc.
  • 5. European Medicines Agency
  • 6. Genesis BioPharma
  • 7. Grifols, S.A.
  • 8. Kedrion S.p.A.
  • 9. Lee Biosolutions, Inc.
  • 10. LFB USA, Inc.
  • 11. Merck KGaA
  • 12. Octapharma AG
  • 13. Scripps Laboratories, Inc.
  • 14. Siemens AG
  • 15. SK Plasma
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Thermo Fisher Scientific Inc.
  • 18. WebMD, LLC

LIST OF FIGURES

  • FIGURE 1. ANTITHROMBIN MARKET RESEARCH PROCESS
  • FIGURE 2. ANTITHROMBIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTITHROMBIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTITHROMBIN MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY GOAT MILK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY ANTICOAGULANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY ANTIPLATELET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY THROMBOLYTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2023